Dasatinib

B-Cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Small moleculePhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 89/ 100

Competitive context

135 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.

Asset / Sponsor	Phase	Rating
Etoposide University of Washington	Phase 3	BBB
Vincristine Sulfate City of Hope Medical Center	Phase 3	BB
Crisantaspase City of Hope Medical Center	Phase 3	BB
Nivestim University of Washington	Phase 3	BB
Pegaspargase National Cancer Institute (NCI)	Phase 3	BB

View all 50 →

Same molecule, other indications

Dasatinib is also rated in:

chronic myeloid leukemiaDormant

BB

Indicative · Phase 2/3

68 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Active

BB

Indicative · Phase 3

67 / 100

childhood acute lymphoblastic leukemiaActive

BB

Indicative · Phase 3

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.